How do Forecasting Approaches and Methodologies Change Through the Product Lifecycle?
Pharma forecasting is not a “one and done” activity. The life of a drug – from a glint in the clinician’s eye, to an established therapy heading towards loss of exclusivity – is a long and complex one. And forecasting for each stage of that lifecycle is very different. In this short video, I highlight […]
BIO-Europe Spring: Pharma Dealmaking in Lisbon
CNS may finally be emerging from its long discussed graveyard. Oncology dealmaking is becoming more selective. And sourcing innovation from China is no longer something to be coy about. These were some of my takeaways from BIO-Europe Spring in Lisbon last week, where the Evaluate team was on the ground sharing data led insight on […]
Highlights of the Orphan Drugs Report by its Creators
For the past few years, Melanie Senior and Andreas Hadjivasiliou have worked together to deliver Evaluate’s annual Orphan Drugs report. They charted the rise and rise of drugs for rare diseases, and discussed the ever-changing market landscape for this fascinating, high risk and hugely important corner of the pharmaceutical industry. In this short video, Melanie […]
How We Build the Analysis Behind Our Orphan Drugs Report
How do we Create the Analysis for our Orphan Drugs Report? Insight is the cornerstone of our annual orphan drugs report, and all that insight and analysis starts with the enormous wealth of data within Evaluate Pharma. If you’ve ever wondered how we build out all this analysis, you’re in luck! In this super-short video, […]
Three Things we Learned in our 2026 Orphan Drugs Webinar
Orphan drugs are forecast to make up 21% of all prescription drug sales by 2032, according to Evaluate forecasts. So it’s hardly surprising that we had a lot of interest in our latest orphan drugs market webinar. If you missed it, you can find the on-demand version here. If you’re saving that treat for later, […]
What Does Dealmaking Tell Us About the Therapies of Tomorrow?
Our upcoming Unlocking Innovation webinar analyzes dealmaking activity to identify mechanisms and technologies that have been trending in recent years, beyond ADCs or GLP-1s. While these two modalities have dominated headlines and investor interest, thanks to their blockbuster potential in oncology and metabolic disease, there’s a broader wave of innovation that could shape the future […]
It’s Time to Act: Why Trump is good for European Biopharma…
Call it a kick up the backside. For decades, Europe has failed to address its biopharma weaknesses – too little lab-to-drug translation, too little scale-up capital, non-existent public markets and penny-pinching drug budgets. Then came President Trump. Love him or hate him, his call-out of the US-EU drug pricing gap, his tariff-talk and his efforts […]
Ready for a Cliffhanger? Register for our Loss of Exclusivity Webinar
For the past few years, our annual World Preview report has included analysis of the potential scale of the 2025-2030 pharma patent cliff. It’s one of the features that garners the most questions from readers, particularly around how a potential loss of $300bn can sit alongside forecast growth of over 7% in the same time […]
How Can Analogs Help Pharma Companies Forecast Effectively?
When you’re bringing a new drug to market, one of the many forecasting challenges is the ability to root your forecasts in reality. This is where analogs come in. Analogs are a really powerful forecasting tool and by selecting a suite of analogs can enable forecasters to take the past and use it as a […]
When Every Decision Counts: Equipping Pharma Sales Teams for Market Success
Therapies entering new therapeutic spaces bring unique challenges; not only to pharmaceutical companies, but to the HCPs entrusted with their use and the patients whose outcomes depend on them. In markets with limited precedent, every clinical decision carries financial, emotional, and procedural weight. Healthcare professionals need clarity on treatment value across different patient volumes, transparent […]
